MacroGenics
About
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics for cancer, autoimmune disorders, and infectious diseases. They leverage proprietary technology platforms like DART® and Trident™ to create bispecific and trispecific antibodies that target multiple antigens or cells, aiming to enhance the immune system's ability to fight disease. The company has a pipeline of product candidates and strategic collaborations with global pharmaceutical companies.
Key facts
At-a-glance profile data
- Website
- macrogenics.com
- Headquarters
- Rockville, United States
- Founded
- 2000
- Total funding
- $14M (Series A)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 25 Sept 2001 | Series A | $14M | Interwest Partners, MPM Capital, OrbiMed |
Tech stack
Detected on macrogenics.com, last scanned 22 Sept 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Analytics 4
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Email provider
- Microsoft 365
- Cookie consent
- OneTrust
Add first review
Frequently asked
How much funding has MacroGenics raised?
MacroGenics has raised a total of $14M in funding. The most recent round on record is Series A.